SCHEMBL24095940

SCHEMBL24095940

CCCCCCCC(=O)N[C@H](CC(N)=O)c1cn(C(C)(C)C)nn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
FAAH O00519 1/20 0.40
MAPK1 P28482 1/20 0.40
DNM1 Q05193 1/20 0.39
GAA P10253 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
PTPN1 P18031 1/20 0.36
SMPD2 O60906 2/20 0.36
SMPD1 P17405 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ASAH1 Q13510 1/20 0.36
ACER2 Q5QJU3 1/20 0.36
CNR2 P34972 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PLA2G2C Q5R387 2/20 0.35
NOD1 Q9Y239 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24096062 0.86 KMT2A (0.40) KMT2AMEN1FAAHMAPK1DNM1
SCHEMBL24096114 0.79 EPHX2 (0.41) KMT2AMEN1FAAHALDH1A1ASAH1
SCHEMBL24095931 0.79 KMT2A (0.39) KMT2AMEN1FAAHMAPK1DNM1
SCHEMBL24095986 0.74 KMT2A (0.43) KMT2AMEN1FAAHMAPK1DNM1
SCHEMBL24095971 0.73 MEN1 (0.40) KMT2AMEN1FAAHMAPK1DNM1
SCHEMBL24096157 0.73 MEN1 (0.40) KMT2AMEN1FAAHMAPK1DNM1
SCHEMBL24095996 0.72 EPHX2 (0.47) FAAHCNR2
SCHEMBL24095985 0.71 MEN1 (0.38) KMT2AMEN1FAAHMAPK1DNM1
SCHEMBL24095927 0.71 FAAH (0.38) KMT2AMEN1FAAHMAPK1DNM1
SCHEMBL24096074 0.71 FAAH (0.42) KMT2AMEN1FAAHMAPK1DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME SENDA BIOSCIENCES INC (US) 2023-07-27 US disclosed
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME SENDA BIOSCIENCES INC (US) 2023-07-27 US disclosed
WO-2021252640-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME SENDA BIOSCIENCES, INC. (US) 2021-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME ASNS, SI, NARS1 KMT2A 4069/4885MEN1 433/4885FAAH 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.